Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban.

MLA

Lin, Yu-Sheng, et al. “Mortality Associated with the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Cancer Patients: Dabigatran versus Rivaroxaban.” Cancer Medicine, vol. 10, no. 20, Oct. 2021, pp. 7079–88. EBSCOhost, https://doi.org/10.1002/cam4.4241.

APA

Lin, Y.-S., Kuan, F.-C., Chao, T.-F., Wu, M., Chen, S.-W., Chen, M.-C., Chung, C.-M., Chu, P.-H., Lip, G. Y. H., & Wu, V. C.-C. (2021). Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban. Cancer Medicine, 10(20), 7079–7088. https://doi.org/10.1002/cam4.4241

Chicago

Lin, Yu-Sheng, Feng-Che Kuan, Tze-Fan Chao, Michael Wu, Shao-Wei Chen, Mien-Cheng Chen, Chang-Ming Chung, Pao-Hsien Chu, Gregory Y H Lip, and Victor Chien-Chia Wu. 2021. “Mortality Associated with the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Cancer Patients: Dabigatran versus Rivaroxaban.” Cancer Medicine 10 (20): 7079–88. doi:10.1002/cam4.4241.